Ab­b­Vie dis­cards PhI­Ib au­toim­mune drug from 10-year-old dis­cov­ery pact, cit­ing chron­ic tox­i­col­o­gy study

When Ab­bott spun out its R&D group in­to Ab­b­Vie back in 2013, it al­so hand­ed off a drug dis­cov­ery deal that it had struck just months pri­or with an­oth­er spin­out — the French biotech In­ven­ti­va — around small mol­e­cule drugs that tar­get RORγ, a pro­tein of­ten found on im­mune cells, to treat au­toim­mune dis­eases.

Over the years, Ab­b­Vie took over the re­sult­ing drug, named it AB­BV-157 (cedirogant), and moved it in­to Phase IIb. But the phar­ma gi­ant is now wind­ing down the whole pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER